Choking

National Choking Awareness Day -- No More Needless Suffering Thanks to LifeVac

Retrieved on: 
Wednesday, March 1, 2023
Death, Food, Choking, Brain, School, Emergency, Emergency medicine, Water, Oxygen, Hospital, Toy, Pharmaceutical industry

National Choking Awareness Day is on March 28th and is an excellent opportunity to take a moment to reflect on the relevancy of this tragedy.

Key Points: 
  • National Choking Awareness Day is on March 28th and is an excellent opportunity to take a moment to reflect on the relevancy of this tragedy.
  • In fact, in the last several months alone there have been four recorded choking deaths of children in schools in the United States.
  • The tide is turning on choking emergencies, but the fight is far from over.
  • The team at LifeVac wants people everywhere to use March 28th as a day of national reflection on how we can work together to put a stop to choking deaths once and for all.

AMO Pharma Announces MHRA Confirmation of CDM1-RS as Approvable Primary Outcome Measure in Myotonic Dystrophy

Retrieved on: 
Monday, February 27, 2023
Medicine, Innovation, Therapy, University, Choking, Wales, Myotonic dystrophy, National Institute for Health and Care Excellence, Phenotype, DM, SMC, FDA, NHS, Regulation of tobacco by the U.S. Food and Drug Administration, AMO, MHRA, DM1, National Health Service, Birth defect, Muscular dystrophy, Healthcare Improvement Scotland, Professor, Caregiver, Tideglusib, Food, TDP, Health care, NICE, Pharmaceutical industry

LONDON, Feb. 27, 2023 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that the Congenital DM1 Rating Scale (CDM1-RS) can be considered an approvable primary outcome measure in clinical trials to develop a treatment for congenital myotonic dystrophy type 1 (CDM1). 

Key Points: 
  • Following advice from the U.S. Food and Drug Administration (FDA), the scale was incorporated by AMO Pharma into the REACH-CDM pivotal study in CDM1.
  • The MHRA reviewed data from AMO Pharma on how the scale was developed using information from natural history studies, consultation with therapeutic area experts and feedback from patient advocates.
  • The MHRA concluded the measure could be considered an approvable primary outcome measure in the event of a positive result in the REACH-CDM study of AMO-02 in CDM1.
  • In December 2022 AMO Pharma announced completion of patient enrollment in the company's REACH-CDM study of the investigational therapy AMO-02 (tideglusib) for the treatment of congenital myotonic dystrophy.

AMO Pharma Announces MHRA Confirmation of CDM1-RS as Approvable Primary Outcome Measure in Myotonic Dystrophy

Retrieved on: 
Monday, February 27, 2023
Medicine, Innovation, Therapy, University, Choking, Wales, Myotonic dystrophy, National Institute for Health and Care Excellence, Phenotype, DM, SMC, FDA, NHS, Regulation of tobacco by the U.S. Food and Drug Administration, AMO, MHRA, DM1, National Health Service, Birth defect, Muscular dystrophy, Healthcare Improvement Scotland, Professor, Caregiver, Tideglusib, Food, TDP, Health care, NICE, Pharmaceutical industry

LONDON, Feb. 27, 2023 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that the Congenital DM1 Rating Scale (CDM1-RS) can be considered an approvable primary outcome measure in clinical trials to develop a treatment for congenital myotonic dystrophy type 1 (CDM1). 

Key Points: 
  • Following advice from the U.S. Food and Drug Administration (FDA), the scale was incorporated by AMO Pharma into the REACH-CDM pivotal study in CDM1.
  • The MHRA reviewed data from AMO Pharma on how the scale was developed using information from natural history studies, consultation with therapeutic area experts and feedback from patient advocates.
  • The MHRA concluded the measure could be considered an approvable primary outcome measure in the event of a positive result in the REACH-CDM study of AMO-02 in CDM1.
  • In December 2022 AMO Pharma announced completion of patient enrollment in the company's REACH-CDM study of the investigational therapy AMO-02 (tideglusib) for the treatment of congenital myotonic dystrophy.

ManukaGuard Promotes Research, Awareness and Education for Kids ENT Health Month

Retrieved on: 
Thursday, February 23, 2023
Research, General Health, Online Retail, Specialty, Consumer, Fitness & Nutrition, Retail, Children, Science, Alternative Medicine, Vitamins, Supplements, Health, Bacteria, Common, Diagnosis, Immune system, Choking, Virus, IG, Ear, Immunity, Nose, Sinusitis, Nature, Parent, Caregiver, Education, Gear, Otitis, Edible, Dentistry, Vaccine

In honor of February being designated as Kids ENT Health Month, ManukaGuard , the nation’s leading provider of natural, medical grade manuka honey products, is calling for more research, enhanced education, and public awareness of pediatric diseases and conditions related to the ear, nose and throat – with an emphasis on illness prevention.

Key Points: 
  • In honor of February being designated as Kids ENT Health Month, ManukaGuard , the nation’s leading provider of natural, medical grade manuka honey products, is calling for more research, enhanced education, and public awareness of pediatric diseases and conditions related to the ear, nose and throat – with an emphasis on illness prevention.
  • From earaches to choking hazards, to repetitive sinus infections and flu, kids suffer from a variety of ailments that require prompt diagnosis and treatment.
  • Kids ENT Health Month is a yearly campaign held every February to offer parents and caregivers the latest information and resources about pediatric ear, nose, and throat disorders.
  • “Honestly, every month should be Kids ENT Health Month,” added Gear.

Global Nano Dentistry Market Report 2022: Enhanced Chewing Abilities Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023
Dental, Health, Journal of Indian Society of Pedodontics and Preventive Dentistry, Jaw, Tooth wear, World Health Organization, Magnetic resonance, Corrosion, Nanorobotics, Prosthodontics, Quantum, Nanomaterials, Projection, Dentures, Maintenance, Choking, Tooth loss, Polymer, Radioactive decay, Mouth, Nanotechnology, Food, Dendrimer, Nanoshell, Crown, Application, Dental care, Ceramic, Tongue, Growth, Nano, Nanocomposite, Dental implant, Dentistry, Hospital

The "Global Nano Dentistry Market Size, Share & Industry Trends Analysis Report By Material Type (Nano Ceramics, Nano Fillers, Nano Robots), By End User (Dental Clinics, Hospitals), By Application, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nano Dentistry Market Size, Share & Industry Trends Analysis Report By Material Type (Nano Ceramics, Nano Fillers, Nano Robots), By End User (Dental Clinics, Hospitals), By Application, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Nano Dentistry Market size is expected to reach $1.5 billion by 2028, rising at a market growth of 10.6% CAGR during the forecast period.
  • Based on the material type, the nano dentistry market is segmented into nano ceramics, nano fillers, nano robots, and others.
  • On the basis of application, the nano dentistry market is divided into preventive dentistry, tooth restoration, dental implants, and others.

LifeVac Partners with ENY Youth Soccer Association

Retrieved on: 
Thursday, February 2, 2023
Life, Football, BLS, Hope, Choking, Inauguration, ENY, Partnership, Conference, Association football, Sport

LONG ISLAND, N.Y., Feb. 2, 2023 /PRNewswire/ -- LifeVac is proud to announce a partnership with the Eastern New York Youth Soccer Association, in which they will be the Presenting Sponsor of the Inaugural season of the Eastern New York National League Conference Qualifier (ENYNLQ). The league will feature Under-12 and Under-13 teams, both boys' and girls', with each division champion being promoted into the US Youth Soccer National League Conference.

Key Points: 
  • The league will feature Under-12 and Under-13 teams, both boys' and girls', with each division champion being promoted into the US Youth Soccer National League Conference.
  • ENYYSA and LifeVac believe all youth soccer players and clubs should have the opportunity to play and compete at the highest levels, regardless of club size and status.
  • We are in the business of saving lives and we believe all youth soccer teams and families should have a LifeVac.
  • This investment in Eastern NY Youth Soccer will help save lives as all ENYNLQ League member teams, will receive a complimentary LifeVac and funds will also broaden the scope and the impact of the league in the community," said Arthur Lih, LifeVac Founder, and CEO.

Global Nano Dentistry Market Report 2022: Sector to Reach $1.5 Billion by 2028 at a 10.6% CAGR

Retrieved on: 
Friday, January 27, 2023
Dentures, Dental implant, Jaw, Quantum, Nanorobotics, Mouth, Dental care, Journal of Indian Society of Pedodontics and Preventive Dentistry, Magnetic resonance, Tongue, Maintenance, Ceramic, Nanomaterials, Radioactive decay, Food, Polymer, Nanocomposite, Crown, Nano, Prosthodontics, Application, Growth, Choking, World Health Organization, Corrosion, Tooth wear, Dendrimer, Tooth loss, Nanoshell, Nanotechnology, Projection, Dentistry, Hospital

The Global Nano Dentistry Market size is expected to reach $1.5 billion by 2028, rising at a market growth of 10.6% CAGR during the forecast period.

Key Points: 
  • The Global Nano Dentistry Market size is expected to reach $1.5 billion by 2028, rising at a market growth of 10.6% CAGR during the forecast period.
  • Based on the material type, the nano dentistry market is segmented into nano ceramics, nano fillers, nano robots, and others.
  • The nano ceramics segment acquired the highest revenue share in the nano dentistry market in 2021.
  • On the basis of application, the nano dentistry market is divided into preventive dentistry, tooth restoration, dental implants, and others.

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

Retrieved on: 
Monday, January 30, 2023
Royal commission, Inflammation, Immunology, Bruise, Eosinophilic esophagitis, Safety, Conjunctivitis, European Commission, Eosinophilia, Ageing, EC, Esophagus, Medicare Part D, Patient, Union, Arthralgia, Regeneron Pharmaceuticals, DSQ, Choking, Infection, Pain, International development, Pharmaceutical industry, Medical imaging, EU, Sanofi, EOE, Dupilumab, Part

TARRYTOWN, N.Y. and PARIS, Jan. 30, 2023 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) expanded the marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to treat eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat EoE in Europe and the U.S.

Key Points: 
  • EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.
  • With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat EoE in Europe and the U.S.
    “This latest approval establishes Dupixent as the only targeted medicine specifically indicated for eosinophilic esophagitis in the European Union.
  • “Since its first approval, Dupixent has redefined the treatment of certain chronic diseases with underlying type 2 inflammation and is now indicated for five conditions in the European Union.
  • The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved indications.

Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis

Retrieved on: 
Monday, January 30, 2023
Inflammation, Bruise, Eosinophilic esophagitis, Safety, Conjunctivitis, European Commission, Eosinophilia, Ageing, EC, Esophagus, Alveolar soft part sarcoma, Patient, Union, Arthralgia, DSQ, Choking, Infection, Pain, Pharmaceutical industry, Medical imaging, EU, EOE, Dupilumab, Part

EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.

Key Points: 
  • EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.
  • Since its first approval, Dupixent has redefined the treatment of certain chronic diseases with underlying type 2 inflammation and is now indicated for five conditions in the European Union.
  • The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved indications.
  • The safety profile through 52 weeks was generally consistent with the safety profile observed at 24 weeks.

Canadian Company Think Meta Enters the American Market

Retrieved on: 
Friday, January 27, 2023
Mentorship, Education, Meta, Mental health, Choking, Psychology, Catalysis, MCP, Knowledge, Thought, Growth, Neuroscience, Research, Metacognition, Behavior, Physician, Cognition, Tutoring

The company has grown exponentially since its founding in 2018 and brings in $30 million per year, with over 50,000 clients worldwide.

Key Points: 
  • The company has grown exponentially since its founding in 2018 and brings in $30 million per year, with over 50,000 clients worldwide.
  • Founder and CEO of Think Meta, Misha Saidov, who is also the founder of IMCP (Institute of Metacognitive Programming), created THE CATALYST program for new and established coaches, entrepreneurs, and business owners.
  • Clients across the US will now have access to the Think Meta coaching program, in which they gain access to the MCP (Metacognitive Programming), a unique coaching technique and specific coaching tools exclusive to Think Meta.
  • Think Meta is a mental health and life performance management platform based in Toronto, Canada, now also serving the US.